Home  About us  Contact
 

Quantitative Flow Cytometry (quantitative + flow_cytometry)

Distribution by Scientific Domains
Medical Sciences100%

Selected Abstracts

Duplexed On-Microbead Binding Assay for Competitive Inhibitor of Epidermal Growth Factor Receptor by Quantitative Flow Cytometry

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY, Issue 1 2010
Wen-Jun Lan
Conventional methods for evaluation of EGFR inhibitors are limited. This study describes a duplexed on-microbead binding assay allowing competitive EGFR inhibitors to be quantificationally evaluated in vitro. Polystyrene microbeads barcoded by fluoresceine isothiocyanate fluorescence as high brightness and low brightness microspheres were coated with receptor tyrosine kinase (RTK) ligand-epidermal growth factor (EGF)/stem cell factor (SCF) and ATP/GTP, respectively. High and low brightness microbeads were mixed and incubated with EGFR and its competitive inhibitor in binding assay buffer. Phycoerythrin (PE) fluorescence-labelled antibody was employed to report the level of EGFR binding to EGF/SCF and ATP/GTP. Values were numbered via PE molecules assessed by quantitative flow cytometry. Results from this study demonstrated that incubation with EGFR identified by PE-labelled antibody can make EGF- and ATP-coated microbeads luminous. And EGF or ATP-competitive EGFR inhibitors, respectively, alleviated this in a concentration-dependent manner. Coating microbeads with SCF or GTP as a negative control cannot capture EGFR. The duplexed on-microbead binding assay in this study might be useful for discovering ligand- and ATP-competitive EGFR inhibitors in a rapid and quantificational approach. [source]

Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin ,6

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, Issue 5 2007
David M. Smadja
Abstract In vitro expansion of late endothelial progenitor cells (EPCs) might yield a cell therapy product useful for myocardial and leg ischaemia, but the influence of EPC expansion on the angiogenic properties of these cells is unknown. In the present study, we investigated the effect of in vitro EPC expansion on vascular endothelial growth factor (VEGF) receptor expression. EPCs were obtained from CD34+ cord blood cells and expanded for up to 5 weeks. Real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) showed that VEGFR2 expression, contrary to VEGFR1 and VEGFR3 expression, was significantly higher on expanded EPCs than on freshly isolated CD34+ cells or on human umbilical vein endothelial cells (HUVECs). Quantitative flow cytometry confirmed that VEGFR2 density on EPCs increased during the expansion process and was significantly higher than on HUVECs. The impact of VEGFR2 increase was studied on the three theoretical steps of angiogenesis, i.e., EPC proliferation, migration and differentiation. VEGFR2 up-regulation had no effect on VEGF-induced cell proliferation, but significantly enhanced EPC migration and pseudotubes formation dependent on integrin ,6 subunit overexpression. In vitro expansion of late EPCs increases the expression of VEGFR2, the main VEGF receptor, with possible implications for EPC-based angiogenic therapy. [source]

A standardized procedure for quantitation of CD11b on polymorphonuclear neutrophil by flow cytometry: potential application in infectious diseases

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, Issue 3 2004
V. Latger-Cannard
Summary An up-regulation of the surface marker CD11b has been demonstrated during polymorphonuclear (PMN) cell activation. CD11b over-expression is often associated with inflammation and is considered as an early marker of infection. However, the absence of standardized assay and the variability of preanalytical settings leading to PMN artifactual activation have compromised the interest of this marker. In the present study a standardized quantitative flow cytometry assay directly performed in whole blood has been used to determine CD11b expression on PMN cells. The results indicate that quantitative flow cytometry can provide consistent CD11b density values between laboratories provided that a calibration system is used including specific calibrators, reagents and protocols. This method allowed us to evidence an up-regulation of CD11b expression for infected patients. This quantitation is a standardized and potentially useful method in clinical situations implying quantitative CD11b expression variations. [source]

Duplexed On-Microbead Binding Assay for Competitive Inhibitor of Epidermal Growth Factor Receptor by Quantitative Flow Cytometry

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY, Issue 1 2010
Wen-Jun Lan
Conventional methods for evaluation of EGFR inhibitors are limited. This study describes a duplexed on-microbead binding assay allowing competitive EGFR inhibitors to be quantificationally evaluated in vitro. Polystyrene microbeads barcoded by fluoresceine isothiocyanate fluorescence as high brightness and low brightness microspheres were coated with receptor tyrosine kinase (RTK) ligand-epidermal growth factor (EGF)/stem cell factor (SCF) and ATP/GTP, respectively. High and low brightness microbeads were mixed and incubated with EGFR and its competitive inhibitor in binding assay buffer. Phycoerythrin (PE) fluorescence-labelled antibody was employed to report the level of EGFR binding to EGF/SCF and ATP/GTP. Values were numbered via PE molecules assessed by quantitative flow cytometry. Results from this study demonstrated that incubation with EGFR identified by PE-labelled antibody can make EGF- and ATP-coated microbeads luminous. And EGF or ATP-competitive EGFR inhibitors, respectively, alleviated this in a concentration-dependent manner. Coating microbeads with SCF or GTP as a negative control cannot capture EGFR. The duplexed on-microbead binding assay in this study might be useful for discovering ligand- and ATP-competitive EGFR inhibitors in a rapid and quantificational approach. [source]

Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia

BRITISH JOURNAL OF HAEMATOLOGY, Issue 6 2003
Eric D. Hsi
Summary. CD38 expression on chronic lymphocytic leukaemia (CLL) cells is a poor prognostic factor, however, methods for measuring this vary. The QuantiBRITETM flow cytometry (FC) system yields an absolute antigen expression value (antibodies bound/cell, ABC) and may be useful in standardizing CD38 expression analysis. We evaluated cryopreserved pretreatment CLL cells for CD20 ABC, CD38 ABC, and percentage of CD38+ B cells from 131 patients requiring therapy. The 92 patients (70%) with , 100 CD38 ABC had worse overall survival (OS; 34% at 5 years) compared with those with <,100 CD38 ABC (70% at 5 years, mortality hazard ratio 2·30, 95% confidence interval 1·28,4·12; two-tailed P = 0·003). Among the 64 patients with <,30% CD38+ cells, OS of the 25 with , 100 ABC was worse than that of the 39 with <,100 ABC (P = 0·018). OS of patients with <,30% CD38+ cells and , 100 ABC was actually similar to that of patients with , 30% CD38+ cells. BrightCD20 expression (, 20 000 ABC) was not associated with a worse OS (P = 0·10). The presence of , 100 CD38 ABC in CLL patients requiring therapy is an unfavourable prognostic factor for OS and quantitative FC may be superior to percentage CD38+ cell assessment. Prospective trials are required to determine more precisely the prognostic significance of absolute expression levels in fresh CLL cells. [source]